Hemato Oncology Testing Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The Hemato Oncology Testing Market is segmented by Product & Services (Assay Kits and Reagents, Services), Cancer Type (Leukemia, Lymphoma, and Other Cancers), Technology (Polymerase chain reaction (PCR), Immunohistochemistry (IHC), Next-Generation Sequencing (NGS), and Other Technology), End-User (Hospitals, Academic & Research Institutes, Other End-Users) and Geography (North America, Europe, Asia-Pacific, Middle East, and Africa, and South America). The report offers the value (in USD million) for the above segments.

Market Snapshot

Hemato Oncology Testing
Study Period: 2019-2027
Base Year: 2021
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 5 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The Hemato Oncology Testing Market is expected to register a CAGR of nearly 5% during the forecast period.

The COVID-19 outbreak has significantly impacted the availability of hospital resources worldwide. This has been primarily managed by dramatically reducing inpatient and outpatient services for other diseases and implementing infection prevention and control measures. The number of hemato cancer testing procedures declined precipitously, with countries worldwide being affected by the pandemic. For instance, an article titled, ‘Hemato-Oncology Care in COVID-19 Pandemic: Crisis within a Crisis’ published on May 2020 reported that the armamentarium necessary for the management of hemato-oncology testing, included all types of blood components, antibiotics, antifungals, chemotherapy; well-trained staff (doctors, laboratory staff, nurses, counselors); financial, and social work support; all of which are often can be used were in short of supply. Also, the lack of beds in most health facilities leads to admission delays, and overutilization of available space, thereby, increasing the infection rates. Thus, the market witnessed significant challenges during the initial phase of lockdown, but as the SARS-CoV-2 cases started decreasing, and with ease in the government lockdown policies, the shortage of hemato oncology testing products were fulfilled and the market witnessed significant growth over time.

The factors that are driving this market are the increasing incidence of hematologic cancer and the growing demand for personalized therapy. The International Agency for Research on Cancer, GLOBOCAN 2020 database reported that globally 475 thousand leukemia cases were reported in 2020 and this number is expected to increase to 692 thousand by 2040. Similarly, in 2022 the Centre for Disease Control and Prevention (CDC) reported the prevalence of Hodgkin’s lymphoma in 2020 was 3.5/1,00,000 for young adults, 2.5/1,00,000 for middle-aged adults, and 3.5/1,00,000 for older adults. Such a high rate of hematologic cancer cases is leading to the increase in demand for hemato oncology testing, thereby driving the demand for products and services associated with it. Thus, the high incidence of hematology cancer cases is driving the studied market.

The growing demand for personalized therapy is also significantly driving the market. Personalized medicine aims to provide tailor-made therapies to individual patients, depending on the molecular basis of the disease, and it has become popular over recent years. The rise in the prevalence of various types of cancer, affordability of personalized medicine therapy in cancer drugs and various other disease indications, fewer side-effects of personalized medicine therapy, high adoption in developed markets, and development of innovative drugs are factors driving this personalized medicine segment. For instance, in August 2022, the Medical Device Innovation Consortium launched its somatic reference samples (SRS) initiative with a pilot project to improve the validation and regulatory review process for cancer diagnostics based on next-generation sequencing (NGS). These diagnostic tests need to be validated for accurate clinical use, and reference samples are essential to the validation process. Additionally, the launch of products is also propelling the growth of the market. For instance, in May 2022 Genes2Me launched next-generation sequencing (NGS) based clinical panels for oncology, personalized medicine, and hereditary diseases in India.

Thus, due to the aforesaid-mentioned reasons, the market is expected to witness significant growth over the forecast period. However, unfavorable reimbursement scenarios may slow down the growth of the studied market.

Scope of the Report

As per the scope, hematology-oncology refers to the science which is associated with the diagnosis, treatment, and prevention of blood-related diseases and cancer. The Hemato Oncology Testing Market is segmented by Product & Services (Assay Kits and Reagents, Services), Cancer Type (Leukemia, Lymphoma, and Other Cancers), Technology (Polymerase chain reaction (PCR), Immunohistochemistry (IHC), Next-Generation Sequencing (NGS), and Other Technology), End-User (Hospitals, Academic & Research Institutes, Other End-Users) and Geography (North America, Europe, Asia-Pacific, Middle East, and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value (in USD million) for the above segments.

By Product & Services
Assay Kits and Reagents
Services
By Cancer Type
Leukemia
Lymphoma
Other Cancers
By Technology
Polymerase chain reaction (PCR)
Immunohistochemistry (IHC)
Next-Generation Sequencing (NGS)
Other Technology
By End User
Hospitals
Academic & Research Institutes
Other End-Users
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa
GCC
South Africa
Rest of Middle East and Africa
South America
Brazil
Argentina
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Services Segment is Expected to Witness Significant Growth over the Forecast Period.

The services segment is expected to dominate the global hemato oncology test market over the forecast period. This can be attributed to increasing awareness of advanced therapies such as personalized medicine and the rising prevalence of leukemia, non-Hodgkin lymphoma, and myeloma cancers. Apart from this, rising awareness regarding advanced treatment therapies such as personalized medicine is also driving the growth of this segment. 

Precision medicine is a new tailor also known as individualized medicine is a healthcare approach that is based on each patient’s unique genetic makeup as opposed to traditional medicine. For instance, in May 2022, the Qatar Genome Program (QGP), a division of the Qatar Foundation (QF), and Thermo Fisher Scientific entered into a partnership to advance genomic research and clinical applications of predictive genomics in Qatar as a step toward extending the advantages of precision medicine across Arab populations globally.

Also, the global high prevalence of leukemia, non-Hodgkin's lymphoma, and myeloma cancer is driving the growth of the studied market. For instance, in 2020 the International research for Research on Cancer, GLOBOCAN database reported that the global incidence of non-Hodgkin's lymphoma was 544 thousand in 2020 and this number is expected to increase by 834 thousand in 2040. The same source also quoted that the global incidence of myeloma cancer was 325 thousand in 2020 and this number is expected to increase to 510 thousand by 2040. Thus, the high incidence of non-Hodgkin's lymphoma and myeloma cancer globally is increasing the demand for hemato oncology services testing, thereby propelling the growth of the studied market. 

Furthermore, the new product launches, technological advancements, and recent development are also leading to the growth of this segment. For instance, in August 2020 Thermo Fisher Scientific announced the introduction of hematology-oncology assays for the Ion Torrent Genexus System. Hence all these factors will help in driving the segment growth.

Thus, due to the aforesaid mentioned reasons, the segment is expected to witness significant growth over the forecast period, thereby fueling the growth of the studied market.

Cancer

North America Region is Expected to Witness Significant Growth over the Forecast Period.

North America is at the forefront of growth in the region and is also an important revenue contributor in the global arena. The large share of this segment can primarily be attributed to the high incidences of hematologic cancer, the aging population, awareness regarding advanced treatment methods, and the strong presence of industry players in the region. These trends are likely to drive market growth during the forecast period.

The rising prevalence of leukemia, lymphoma and multiple myeloma are stimulating the growth of the region. For instance, in 2022 Canada Cancer Society reported that in 2021 6,700 Canadians were diagnosed with leukemia, out of which 4,000 were men and 2,700 were women. Also, in 2022 the American Cancer Society reported that about 60,650 new cases of leukemia and 20,050 new cases of acute myeloid leukemia (AML) were reported in the United States. Acute myeloid leukemia (AML) accounted for only about 1% of all cancers. Thus, the high incidence of blood cancer cases in the region is leading to an increase in hemato oncology testing, thereby driving the market in the region.

Furthermore, favorable initiatives and academic and research organizations are working on hemato-oncology tests. For instance, in August 2022, Mount Sinai Health System and the Icahn School of Medicine launched a new human genome sequencing research project called the Mount Sinai Million Health Discoveries Program with the Regeneron Genetics Center (RGC). The collaboration team plans to combine the RGC’s massive gene sequencing capabilities and scientific research expertise with Mount Sinai’s large, diverse patient population. Such collaboration will lead to the study of the entire human genome, which will lead to the development of better diagnostics for testing various types of cancer including hemato oncology cancer. 

Also, in November 2021, SAN DIEGO and Genetic Alliance today announced the creation of the iHope Genetic Health program aimed at providing whole-genome sequencing access (WGS) to tens of thousands of patients across the globe impacted by genetic disease. Thus, due to the above-mentioned reasons the region is expected to witness significant growth over the forecast period.

123

Competitive Landscape

The Hemato Oncology Testing Market is fragmented and competitive and consists of several major players. In terms of market share, a few of the major players are currently dominating the market. Some of the companies which are currently dominating the market are F. Hoffmann-La Roche Ltd, Abbott, Invitae Corporation (Archerdx, Inc), Qiagen, Thermo Fisher Scientific Inc., Illumina Inc., Bio-Rad Laboratories, Inc., Molecularmd (Subsidiary of Icon PLC), Asuragen, Inc., Arup Laboratories Inc., Icon PLC., Adaptive Biotechnologies, and Invivoscribe, Inc.

Recent Development

  • In August 2022, Thermo Fisher Scientific launched CE-IVD (IVDD) next-generation sequencing test and analysis software to expand access to precision oncology biomarker testing.
  •  In June 2022, Burning Rock Biotech Limited received CE marking for its OverC multi-cancer detection blood test. OverC Multi-Cancer Detection Blood Test is a qualitative next-generation sequencing (NGS)-based in vitro diagnostic device. 

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Assumptions and Market Definition

    2. 1.2 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increasing Incidence of Hematologic Cancer

      2. 4.2.2 Growing Demand for Personalized Therapy

    3. 4.3 Market Restraints

      1. 4.3.1 Unfavorable Reimbursement Scenario

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION (Market Size by Value - USD million)

    1. 5.1 By Product & Services

      1. 5.1.1 Assay Kits and Reagents

      2. 5.1.2 Services

    2. 5.2 By Cancer Type

      1. 5.2.1 Leukemia

      2. 5.2.2 Lymphoma

      3. 5.2.3 Other Cancers

    3. 5.3 By Technology

      1. 5.3.1 Polymerase chain reaction (PCR)

      2. 5.3.2 Immunohistochemistry (IHC)

      3. 5.3.3 Next-Generation Sequencing (NGS)

      4. 5.3.4 Other Technology

    4. 5.4 By End User

      1. 5.4.1 Hospitals

      2. 5.4.2 Academic & Research Institutes

      3. 5.4.3 Other End-Users

    5. 5.5 Geography

      1. 5.5.1 North America

        1. 5.5.1.1 United States

        2. 5.5.1.2 Canada

        3. 5.5.1.3 Mexico

      2. 5.5.2 Europe

        1. 5.5.2.1 Germany

        2. 5.5.2.2 United Kingdom

        3. 5.5.2.3 France

        4. 5.5.2.4 Italy

        5. 5.5.2.5 Spain

        6. 5.5.2.6 Rest of Europe

      3. 5.5.3 Asia-Pacific

        1. 5.5.3.1 China

        2. 5.5.3.2 Japan

        3. 5.5.3.3 India

        4. 5.5.3.4 Australia

        5. 5.5.3.5 South Korea

        6. 5.5.3.6 Rest of Asia-Pacific

      4. 5.5.4 Middle East and Africa

        1. 5.5.4.1 GCC

        2. 5.5.4.2 South Africa

        3. 5.5.4.3 Rest of Middle East and Africa

      5. 5.5.5 South America

        1. 5.5.5.1 Brazil

        2. 5.5.5.2 Argentina

        3. 5.5.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 F. Hoffmann-La Roche Ltd

      2. 6.1.2 Abbott

      3. 6.1.3 Invitae Corporation (Archerdx, Inc)

      4. 6.1.4 QIAGEN

      5. 6.1.5 Thermo Fisher Scientific Inc.

      6. 6.1.6 Illumina Inc.

      7. 6.1.7 Bio-Rad Laboratories, Inc.-

      8. 6.1.8 Molecularmd (Subsidiary of Icon PLC)

      9. 6.1.9 Asuragen, Inc.

      10. 6.1.10 Arup Laboratories Inc.

      11. 6.1.11 Icon PLC

      12. 6.1.12 Adaptive Biotechnologies.

      13. 6.1.13 Invivoscribe, Inc.

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Global Hemato Oncology Testing Market market is studied from 2019 - 2027.

The Global Hemato Oncology Testing Market is growing at a CAGR of 5% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2021.

Abbott, ILLUMINA, INC, Thermo Fisher Scientific, QIAGEN, F. Hoffmann-La Roche Ltd are the major companies operating in Global Hemato Oncology Testing Market .

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!